
Weirdly Hot Rocks in New England Traced to 80-Million-Year-Old Greenland Rift
Researchers have long believed that the NAA resulted from the plate tectonic movement that broke North America off northwest Africa 180 million years ago. In a new study published Tuesday in the journal Geology, however, a team of international researchers argue that the hot, subsurface rocks are related to when North America and Greenland split near the Labrador Sea between 90 and 80 million years ago.
The NAA 'lies beneath part of the continent that's been tectonically quiet for 180 million years, so the idea it was just a leftover from when the landmass broke apart never quite stacked up,' Tom Gernon, lead author of the study and an Earth scientist at the University of Southampton, said in a university statement.
To reach this conclusion, the team used advanced computer simulations, seismic tomography data (like an ultrasound, but for Earth's interior), and tectonic plate reconstructions. According to the study, the NAA may have developed around 1,119 miles (1,800 km) from its current position and, at the rate of around 12 miles (20 km) per million years, slowly moved southwestward to where it sits now.
'Our research suggests it's part of a much larger, slow-moving process deep underground that could potentially help explain why mountain ranges like the Appalachians are still standing,' Gernon added.
The slow-moving process is the team's previously proposed 'mantle wave' theory, which hypothesizes that hot, dense chunks of material detach from the base of tectonic plates after continents separate, like blobs in a lava lamp.
'Heat at the base of a continent can weaken and remove part of its dense root, making the continent lighter and more buoyant, like a hot air balloon rising after dropping its ballast,' Gernon explained. 'This would have caused the ancient mountains to be further uplifted over the past few million years.'
As the blobs slowly 'drip' from the lithosphere—the layer including Earth's crust and upper part of the mantle—hotter mantle rocks rise to fill up the space, which creates a thermal anomaly. The same team's earlier work also revealed that these blobs can move over time.
'The feature we see beneath New England is very likely one of these drips, which originated far from where it now sits,' said Sascha Brune, study co-author and head of the Geodynamic Modelling Section at GFZ, Germany's national research center for Earth sciences. According to the team, the center of the NAA will likely move under New York in the next 15 million years.
'The idea that rifting of continents can cause drips and cells of circulating hot rock at depth that spread thousands of kilometres inland makes us rethink what we know about the edges of continents both today and in Earth's deep past,' admitted Derek Keir, another co-author of the study and a tectonics expert at the University of Southampton and the University of Florence.
The researchers argue that their mantle wave theory could explain a similar anomalous hot zone under north-central Greenland—basically a reflection of the NAA on the other side of the Labrador Sea.
The study is ultimately a reminder to never judge a book by its cover—or the Earth by its surface-level tectonic activity.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Podcast: AAIC 2025 highlights and the latest trends in Alzheimer's disease IVDs
This year's Alzheimer's Association International Conference (AAIC), which took place in Toronto, Canada, on 27-31 July, featured a range of data readouts from companies developing in vitro diagnostics (IVD) for the early diagnosis of Alzheimer's disease. A key theme among many presentations was the use of ALZpath's pTau217 antibody. The biomarker featured in seven presentations and 30 posters. A presentation from Roche shared new real-world data confirming that its blood-based biomarker, Elecsys pTau217, provided comparable results to PET scan and cerebrospinal fluid (CSF) diagnostics for rule-in and rule-out diagnosis of amyloid pathology. Medical Device Network sat down with Selena Yu, senior medical analyst at GlobalData, to learn more about the key IVD news from this year's AAIC and the direction in which Alzheimer's disease research and development is currently headed. You can listen to the podcast below: Este contenido insertado no está disponible en tu región. "Podcast: AAIC 2025 highlights and the latest trends in Alzheimer's disease IVDs" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos
Yahoo
an hour ago
- Yahoo
Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru's Enobosarm, Utilizing Laxxon's SPID®-Technology
NEW YORK, August 11, 2025--(BUSINESS WIRE)--Laxxon Medical Corp., a leading pharmaceutical technology company pioneering a new generation of advanced oral drug delivery systems, today announced that Veru Inc. (NASDAQ: VERU), a late clinical-stage biopharmaceutical company advancing treatments for cardiometabolic and inflammatory diseases, has selected a novel modified-release oral formulation of enobosarm that will utilize Laxxon's proprietary SPID® (Screen Printing Innovation Drug)-Technology. The novel tablet formulation achieved the desired target release profile, including a reduced maximum plasma concentration (Cmax), a delayed time to maximum plasma concentration (Tmax), a distinct secondary peak plasma concentration, and a similar extent of absorption (AUC) compared to historical values for immediate release enobosarm capsules. "This milestone underscores the strength of our SPID®-Technology in enhancing bioavailability and optimizing drug release profiles," said Helmut Kerschbaumer, Chief Executive Officer of Laxxon Medical. "The collaboration with Veru reflects our commitment to advancing next-generation drug formulations, and we are excited to support them on their product development pathway." Sequential release of APIs, processing of molecules like peptides in combination with permeation enhancers, processing of nanoparticles, multi-compartment tablets starting at a micro-tablet dimension as small as < 750 micron, are just some of the various possibilities which SPID®-Technology enables, and multiple other functionalities can be combined in one tablet with the potential upscaling from lab to mass production. "Selecting Laxxon as our formulation development partner was a strategic decision, driven by the strength of their SPID® platform and their proven expertise in advanced drug formulation," said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru. "The resulting modified-release oral formulation of enobosarm has multiple benefits when treating the intended patient population and represents a significant advance over conventional drug product dosage forms as we move towards Phase 3 clinical trials and potential commercialization, pending regulatory approval." About Laxxon MedicalLaxxon Medical Corp. is a leading pharma-technology company and global leader of smart drug delivery systems in the pharmaceutical industry, pioneering a new generation of advanced pharmaceuticals designed to optimize drug delivery and maximize patient success through SPID®-Technology, Laxxon's proprietary screen printing technology platform. SPID®-Technology unlocks innovative drug delivery advancements paired with fast-tracked market access and extensive IP protection to yield disruptive opportunities in drug development and commercialization. With SPID®-Technology, Laxxon can develop and manufacture advanced versions of new and existing pharmaceutical drugs while extending and adding new patent protection through the technology transfer process. Laxxon can fully utilize the FDA's 505b(2) regulatory pathway in the US and Hybrid applications under article 10(3) of Directive 2001/83/EC in the EU, which fast tracks product routes to market. Laxxon's pipeline includes ongoing working-projects with notable pharma players, biotech companies and research universities, in addition to 13 in-house Advanced Patented Generics products. Laxxon's IP is continuously growing, and together with the licensed IP from Exentis Group, consists of >230 patents and patent applications with more than 5,000 patent claims. About Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company's drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, thereby improving body composition and physical function. Sabizabulin, a microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease. For more information, visit View source version on Contacts Laxxon Investor and Media Contacts: IR@ Veru Investor and Media Contact: Samuel FischExecutive Director, Investor Relations and Corporate CommunicationsEmail: veruinvestor@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Philippe Cousteau's EarthEcho International Announces Diverse Youth Advocates Join the Blue Carbon Ambassador Program
WASHINGTON, Aug. 11, 2025 /PRNewswire/ -- EarthEcho International announced today the 14 participants, ages 16-21, selected for an innovative ocean restoration program led by youth from racially marginalized communities. The Blue Carbon Ambassador program provides hands-on professional learning experience designed to introduce participants to the role of blue carbon ecosystems (including kelp, seagrass, mangroves, and salt marshes) in fighting the climate crisis. The Ambassadors, hailing from frontline coastal communities in North America, will develop their own projects to support the restoration of blue carbon ecosystems in their local communities. "EarthEcho recognizes that access to our oceans and the chance to build careers in the restorative blue economy remains unequally distributed," said EarthEcho International founder Philippe Cousteau. "This dynamic group of young leaders brings passion, vision, and diverse perspectives to the expanding movement, advancing ocean-based solutions to restore marine ecosystems and build community-centered climate resilience." The Blue Carbon Ambassador Program is made possible through the generous support of La Mer Blue Heart Oceans Fund and The Estée Lauder Companies Travel Retail division. In 2025, Blue Carbon Ambassadors are exploring blue carbon ecosystems and regenerative ocean aquaculture through field experience, expert-led workshops, and peer-to-peer learning exchanges. Projects will be developed this summer and executed between August 2025-March 2026 and are supported by local community based organizations in their regions, including Billion Oyster Project, Seaweed City, Surfrider Puerto Rico, and Lower 9th Ward Center for Sustainable Engagement and Development. Meet the 2025 Blue Carbon Ambassadors:Acadia Li from Vancouver, British Columbia, CanadaAngel Jean-Remy from New York, New York, USAAurora Espasas from Aguas Buenas, Puerto Rico, USABryce Black from New Orleans, Louisiana, USAElizabeth Torres-Priego from New York, New York, USAIsabella Allwood from New York, New York, USAIsabella Negrón Casillas from Bayamón, Puerto Rico, USAJafet Santos-Maldonado from Ensenada, Puerto Rico, USAJafrin Zahir from New York, New York, USAJarelys N. Merle Crespo from Moca, Puerto Rico, USAJyah Hamilton from Harvey, Louisiana, USAPaige Parent from New Orleans, Louisiana, USASofía Nicole Sánchez Villamar from San Juan, Puerto Rico, USASophia Deng from New York, New York, USA For more information about Blue Carbon Ambassadors, please visit For more information about EarthEcho International, visit or follow us on Facebook: Instagram: and Twitter: View original content to download multimedia: SOURCE EarthEcho International